1 completed, 1 recruiting, 1 terminated, 1 unknown. 2 Phase 3, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 4 | 1 | Unknown 1 |
Follow OM 89: new trials by email Literature Review of OM 89 trials Research Report on OM 89
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder OM-89 [Uro-Vaxom® Capsule], OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo] - Neurogenic Bladder | Phase 3 | Recruiting | Centre Hospitalier Universitaire Dijon | 110 | 2024-12-16 | 2026-09-08 |
| The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome OM-89 [Uro-Vaxom® Capsule], OM-89 Placebo [Uro-Vaxom® Capsule Placebo] - Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Chronic Prostatitis | Phase 4 | Unknown | AJU Pharm Co., Ltd. | 332 | 2023-12-20 | 2024-04-04 |
| Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) Uro vaxom, Placebo comparator - UTI, Neurogenic Bladder | Phase 2 | Completed | Buckinghamshire Healthcare NHS Trust | 48 | 2018-04-06 | 2020-03-18 |
| Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED) infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89. - Rheumatoid Arthritis | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 8 | 2007-06-01 | 2017-04-12 |
Urinary Bladder, Neurogenic (2) · Arthritis, Rheumatoid (1) · Multiple Sclerosis (1) · Myelitis, Transverse (1) · Prostatitis (1) · Spinal Cord Injuries (1) · Urinary Tract Infections (1)
AJU Pharm Co., Ltd. (1) · Buckinghamshire Healthcare NHS Trust (1) · Centre Hospitalier Universitaire Dijon (1) · Merck Sharp & Dohme LLC (1)
France (1) · South Korea (1) · United Kingdom (1)
Maurizio Belci, DMS MSc MRCS FRCP (1)
2005 (1)